We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
PacBio's clinical adoption and sequencing innovations support growth despite persistent funding headwinds.
Consumables revenues rose 6% in Q2 2026, while clinical shipments jumped 67% and EMEA revenues surged 52%.
PacBio cut its 2026 revenue guidance to $155-$165 million and delayed its cash flow breakeven target to 2028.
Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, has been gaining from its continued product development. The optimism, led by growing clinical adoption, is expected to contribute further. However, concerns about funding headwinds persist.
In the year-to-date period, this Zacks Rank #3 (Hold) company’s shares have gained 20.4% against the 1% decline of the industry. The S&P 500 Composite has improved 11.3% in the said time frame.
The renowned global provider of sequencing systems has a market capitalization of $699.4 million. The company projects 18.7% growth for 2026 and expects to maintain its strong performance in the future. PacBio’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters, met once, delivering an average surprise of 22.8%.
Image Source: Zacks Investment Research
Factors Favoring PACB’s Growth
Sequencing Technologies Strengthen Market Leadership: PacBio differentiates itself in the genomics industry through its proprietary HiFi long-read sequencing, based on Single-Molecule Real-Time (SMRT) technology. This technology enables the high-accuracy, real-time detection of complex genomic structures, such as structural variations, haplotypes and epigenetic modifications.
Per a report by Data Bridge Market Research, the global SMRT market size was valued at $2.88 billion in 2024 and is projected to reach $4.36 billion by 2032, at a CAGR of 5.3%. Additionally, PacBio expanded its offerings by integrating Sequencing by Binding chemistry and launching its Onso system in 2022, a short-read platform that delivers ≥90% bases at Q40+ accuracy, 15 times more precise than traditional sequencing methods. By offering both long-read and short-read technologies, PacBio uniquely serves diverse research and clinical applications while lowering costs and improving variant detection.
Growing Clinical Adoption and Consumables Support Recurring Growth: PacBio’s growing clinical adoption and expanding installed base are expected to support recurring consumables revenues over time. Second-quarter 2026 consumables revenues rose 6% year over year to $20.1 million, while clinical shipments increased 67%. EMEA revenues surged 52% to $14.4 million as hospitals transitioned from pilot programs to routine sequencing. PacBio shipped 20 Revio systems, up from 15 a year ago, with 60% going to new customers, alongside 26 Vega systems.
However, annualized Revio pull-through declined to approximately $202,000 from $229,000 in the first quarter due to inventory adjustments and SPRQ-Nx workflow validation. Management expects 2026 Revio pull-through of $200,000-$225,000, with improvement anticipated as the transition progresses into late 2026 and 2027. While clinical adoption, multisystem orders and broader installed base offer long-term growth opportunities, converting placements into sustained consumables demand remains key to performance.
Mixed Q2 Results: PacBio exited the second quarter of 2026 with mixed results, as adjusted earnings met the Zacks Consensus Estimate while revenues missed expectations. Growth in consumables revenues, strong clinical demand and higher EMEA revenues provided some support, but softer instrument sales, funding constraints in the Americas and a sharp revenue decline in Asia Pacific weighed on performance.
Additionally, slower-than-expected SPRQ-Nx adoption as customers complete workflow validation, along with higher costs related to memory, compute and the Vega manufacturing transition, continues to pressure profitability. These challenges prompted PacBio to lower its 2026 revenue and gross margin guidance and push its cash flow breakeven target to 2028, highlighting persistent execution and funding-related headwinds.
A Factor That May Offset PACB’s Gains
Funding Headwinds Continue to Weigh on Instrument Demand:PacBio’s second-quarter 2026 results highlight persistent weakness in research-funded markets and challenges associated with the SPRQ-Nx transition, which continue to offset clinical demand. Instrument revenues fell 9% year over year to $12.8 million, while Asia-Pacific revenues declined 45% to $7 million, reflecting funding constraints, lower consumables demand and the completion of a population sequencing program.
Slower SPRQ-Nx adoption, elevated memory and compute costs, Vega manufacturing transition expenses and lower-priced strategic placements also pressured margins. Consequently, management lowered its 2026 revenue guidance to $155-$165 million and non-GAAP gross margin outlook to 35%-37%. PacBio now expects year-end cash of $175-$185 million and has delayed its cash flow breakeven target to 2028 from the end of 2027, underscoring continued execution risks despite planned cost reductions.
Estimate Trend
PacBio has been witnessing a stable estimate revision trend for 2026. Over the past 30 days, the Zacks Consensus Estimate for its adjusted loss per share has remained stable at 43 cents.
The Zacks Consensus Estimate for 2026 revenues is pegged at $156.1 million, indicating a 2.4% decrease from the year-ago reported number.
Key Picks
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. Merit Medical Systems’ earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
Key Takeaways
Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, has been gaining from its continued product development. The optimism, led by growing clinical adoption, is expected to contribute further. However, concerns about funding headwinds persist.
In the year-to-date period, this Zacks Rank #3 (Hold) company’s shares have gained 20.4% against the 1% decline of the industry. The S&P 500 Composite has improved 11.3% in the said time frame.
The renowned global provider of sequencing systems has a market capitalization of $699.4 million. The company projects 18.7% growth for 2026 and expects to maintain its strong performance in the future. PacBio’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters, met once, delivering an average surprise of 22.8%.
Image Source: Zacks Investment Research
Factors Favoring PACB’s Growth
Sequencing Technologies Strengthen Market Leadership: PacBio differentiates itself in the genomics industry through its proprietary HiFi long-read sequencing, based on Single-Molecule Real-Time (SMRT) technology. This technology enables the high-accuracy, real-time detection of complex genomic structures, such as structural variations, haplotypes and epigenetic modifications.
Per a report by Data Bridge Market Research, the global SMRT market size was valued at $2.88 billion in 2024 and is projected to reach $4.36 billion by 2032, at a CAGR of 5.3%. Additionally, PacBio expanded its offerings by integrating Sequencing by Binding chemistry and launching its Onso system in 2022, a short-read platform that delivers ≥90% bases at Q40+ accuracy, 15 times more precise than traditional sequencing methods. By offering both long-read and short-read technologies, PacBio uniquely serves diverse research and clinical applications while lowering costs and improving variant detection.
Growing Clinical Adoption and Consumables Support Recurring Growth: PacBio’s growing clinical adoption and expanding installed base are expected to support recurring consumables revenues over time. Second-quarter 2026 consumables revenues rose 6% year over year to $20.1 million, while clinical shipments increased 67%. EMEA revenues surged 52% to $14.4 million as hospitals transitioned from pilot programs to routine sequencing. PacBio shipped 20 Revio systems, up from 15 a year ago, with 60% going to new customers, alongside 26 Vega systems.
However, annualized Revio pull-through declined to approximately $202,000 from $229,000 in the first quarter due to inventory adjustments and SPRQ-Nx workflow validation. Management expects 2026 Revio pull-through of $200,000-$225,000, with improvement anticipated as the transition progresses into late 2026 and 2027. While clinical adoption, multisystem orders and broader installed base offer long-term growth opportunities, converting placements into sustained consumables demand remains key to performance.
Mixed Q2 Results: PacBio exited the second quarter of 2026 with mixed results, as adjusted earnings met the Zacks Consensus Estimate while revenues missed expectations. Growth in consumables revenues, strong clinical demand and higher EMEA revenues provided some support, but softer instrument sales, funding constraints in the Americas and a sharp revenue decline in Asia Pacific weighed on performance.
Additionally, slower-than-expected SPRQ-Nx adoption as customers complete workflow validation, along with higher costs related to memory, compute and the Vega manufacturing transition, continues to pressure profitability. These challenges prompted PacBio to lower its 2026 revenue and gross margin guidance and push its cash flow breakeven target to 2028, highlighting persistent execution and funding-related headwinds.
A Factor That May Offset PACB’s Gains
Funding Headwinds Continue to Weigh on Instrument Demand:PacBio’s second-quarter 2026 results highlight persistent weakness in research-funded markets and challenges associated with the SPRQ-Nx transition, which continue to offset clinical demand. Instrument revenues fell 9% year over year to $12.8 million, while Asia-Pacific revenues declined 45% to $7 million, reflecting funding constraints, lower consumables demand and the completion of a population sequencing program.
Slower SPRQ-Nx adoption, elevated memory and compute costs, Vega manufacturing transition expenses and lower-priced strategic placements also pressured margins. Consequently, management lowered its 2026 revenue guidance to $155-$165 million and non-GAAP gross margin outlook to 35%-37%. PacBio now expects year-end cash of $175-$185 million and has delayed its cash flow breakeven target to 2028 from the end of 2027, underscoring continued execution risks despite planned cost reductions.
Estimate Trend
PacBio has been witnessing a stable estimate revision trend for 2026. Over the past 30 days, the Zacks Consensus Estimate for its adjusted loss per share has remained stable at 43 cents.
The Zacks Consensus Estimate for 2026 revenues is pegged at $156.1 million, indicating a 2.4% decrease from the year-ago reported number.
Key Picks
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. Merit Medical Systems’ earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.